Loading clinical trials...

Topical Ruxolitinib Evaluation in Chronic Hand Eczema | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema

NCT05906628•Incyte Corporation

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of CHE for at least 6 months prior to screening. Diagnosis of chromic hand eczema (CHE) as defined by hand eczema (HE) lasting \> 3 months or ≥ 2 flares within the previous 12 months.
•Screening and baseline IGA-CHE 3 or 4.
•Baseline CHE-related Itch NRS ≥ 4.
•Have been treated with at least 1 prescription CHE therapy or if such therapy was not advisable or contraindicated.
•Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.

Exclusion Criteria

•Known triggers for CHE (allergic or irritant, such as those identified by previous patch tests) cannot be avoided during the course of this study.
•Any serious illness or medical, physical, or psychiatric condition(s).
•Laboratory values outside of the protocol-defined criteria.
•Use of protocol-defined treatments within the indicated washout period before baseline.
•Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks before baseline.
•Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.

Locations (36)

Southwest Skin Specialists Phoenix Biltmore

Phoenix, Arizona, United States

First Oc Dermatology

Fountain Valley, California, United States

Marvel Clinical Research Llc

Huntington Beach, California, United States

Dermatology Research Associates

Los Angeles, California, United States

Skin Research of South Florida, Llc

Miami, Florida, United States

Well Pharma Medical Research Corporation

Miami, Florida, United States

Forcare Clinical Research

Tampa, Florida, United States

Midwest Allergy Sinus Asthma, Sc

Normal, Illinois, United States

The Indiana Clinical Trials Center Ictc

Plainfield, Indiana, United States

Delricht Research

Baton Rouge, Louisiana, United States

Key Dates

Start Date

July 31, 2023

Primary Completion Date

July 15, 2024

Completion Date

December 13, 2024

Last Updated

July 31, 2025

Enrollment

186

ACTUAL participants

Conditions

Hand Eczema

Interventions

Ruxolitinib cream

DRUG

Vehicle

DRUG

Immune Signature of Chronic Hand Eczema Unveiled by Spatial Transcriptomics and Single-Cell Proteomics

NCT06884163

Hand Eczema

View study

ACTIVE_NOT_RECRUITINGNA

Prevention of Hand Eczema Among Workers in the Fishing Industry in Greenland

NCT06997393

Hand Eczema

View study

COMPLETED

Satisfaction Survey - Cicaplast Mains

NCT05471934

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 31, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Inclusion Criteria

Exclusion Criteria

Immune Signature of Chronic Hand Eczema Unveiled by Spatial Transcriptomics and Single-Cell Proteomics

Prevention of Hand Eczema Among Workers in the Fishing Industry in Greenland

Satisfaction Survey - Cicaplast Mains

Hand Eczema in the Health Care Sector

Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema

Chronic Hand Eczema - Self-management and Prognosis